{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:30:19Z","timestamp":1792794619442,"version":"4.5.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Renal Best Practice"},{"name":"European Renal Association","id":[{"id":"https:\/\/ror.org\/01zpyjx73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"European Reference Network for Rare Kidney Diseases","id":[{"id":"https:\/\/ror.org\/04x2ddb07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A definition of \u2018disease modification\u2019 for kidney disease is long overdue. Here, we propose three key criteria for disease modification in immune-mediated glomerulonephritis and podocytopathies: minimizing disease activity, preventing loss of kidney structure and function, and reducing treatment-related toxicity. To be considered a disease-modifying anti-nephropathic drug (DMAND), a drug must fulfil all three criteria, hence the DMAND status of a drug may not be clear at the time of regulatory approval. Notably, the aspect of chronic kidney disease (CKD) in immune-mediated kidney diseases must be considered and treated separately, e.g. renin\u2013angiotensin system inhibitor is a DMAND for the CKD aspect but not for the immune disease itself. Defining DMANDs is an ambitious goal but one that may help to set the priorities for future treatment strategies in immune-mediated kidney disease. This may mean much more rapid tapering or even avoidance of unselective, non-targeted immunosuppressive agents, which carry considerable short (teratogenicity) and long term risks (malignancies). The criteria proposed here set a high bar for \u2018disease modification\u2019 in immune-mediated kidney disease. Inevitably, this must dictate altered priorities with the focus for new therapeutic agents and strategies shifting from solely reduction of proteinuria to preservation of GFR and attenuation of decline, whilst also eliminating long-term toxicity.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf033","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T07:17:51Z","timestamp":1738912671000},"page":"1243-1247","source":"Crossref","is-referenced-by-count":8,"title":["Disease-modifying anti-nephropathic drugs (DMANDs)\u2014a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA)"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y K Onno","family":"Teng","sequence":"first","affiliation":[{"name":"Leiden University Medical Center Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine\u2014Nephrology Section, , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[{"name":"Limassol General Hospital, State Health Services Organization Department of Nephrology, , Limassol ,","place":["Cyprus"]},{"name":"University of Nicosia Medical School , Nicosia ,","place":["Cyprus"]},{"name":"National and Kapodistrian University of Athens Medical School, , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension, Medical University Innsbruck Department of Internal Medicine IV, , Innsbruck ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-9941","authenticated-orcid":false,"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[{"name":"Medicine and Caring Sciences, Link\u00f6ping University Department of Health, , Link\u00f6ping ,","place":["Sweden"]},{"name":"Karolinska University Hospital and CLINTEC Karolinska Institutet Department of Renal Medicine, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Fontan","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12) Department of Nephrology, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"RWTH Aachen University Hospital Division of Nephrology, , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-4133","authenticated-orcid":false,"given":"Sarah M","family":"Moran","sequence":"additional","affiliation":[{"name":"Cork University Hospital & School of Medicine, University College Cork Department of Nephrology, , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-8154","authenticated-orcid":false,"given":"Safak","family":"Mirioglu","sequence":"additional","affiliation":[{"name":"Aziz Sancar Institute of Experimental Medicine, Istanbul University Department of Immunology, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-1692","authenticated-orcid":false,"given":"Kate I","family":"Stevens","sequence":"additional","affiliation":[{"name":"Queen Elizabeth University Hospital Glasgow Renal and Transplant Unit, , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-494X","authenticated-orcid":false,"given":"Stefanie","family":"Steiger","sequence":"additional","affiliation":[{"name":"Hospital of the Ludwig-Maximilians-University Division of Nephrology, Department of Internal Medicine IV, , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-8088","authenticated-orcid":false,"given":"Paola","family":"Romagnani","sequence":"additional","affiliation":[{"name":"Meyer Children's Hospital IRCCS Nephrology and Dialysis Unit, , Florence ,","place":["Italy"]},{"name":"Experimental and Clinical Sciences \u201cMario Serio\u201d, University of Florence Department of Biomedical, , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-2956","authenticated-orcid":false,"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[{"name":"Hospital of the Ludwig-Maximilians-University Division of Nephrology, Department of Internal Medicine IV, , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"2025053005074398200_bib1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rdc.2005.09.005","article-title":"The definition and measurement of disease modification in inflammatory rheumatic diseases","volume":"32","author":"Aletaha","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"2025053005074398200_bib2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson's","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol"},{"key":"2025053005074398200_bib3","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"},{"key":"2025053005074398200_bib4","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025053005074398200_bib5","article-title":"Guideline on the clinical investigation of medicinal products to prevent development\/slow progression of chronic","author":"Committee for Medicinal Products for Human Use (CHMP)","year":", 2016","journal-title":"EMA\/CHMP\/500825\/2016"},{"key":"2025053005074398200_bib6","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"2025053005074398200_bib7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2025053005074398200_bib8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N Engl J Med"},{"key":"2025053005074398200_bib9","doi-asserted-by":"publisher","first-page":"ii50","DOI":"10.1093\/ndt\/gfad069","article-title":"CKD therapy to improve outcomes of immune-mediated glomerular diseases","volume":"38","author":"Anders","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025053005074398200_bib10","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ndt\/gfad067","article-title":"The five types of glomerulonephritis classified by pathogenesis, activity and chronicity (GN-AC)","volume":"38","author":"Romagnani","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf033\/61813753\/gfaf033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/6\/1243\/61813753\/gfaf033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/6\/1243\/61813753\/gfaf033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:07:48Z","timestamp":1748581668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/6\/1243\/8005963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,8]]},"published-print":{"date-parts":[[2025,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf033","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,8]]}}}